All News
Filter News
Found 192 articles
-
Abeona Therapeutics Reports Second Quarter 2022 Financial Results
8/11/2022
Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in cell and gene therapy, today announced financial results for the second quarter of 2022.
-
Taysha Gene Therapies to Release Second Quarter 2022 Financial Results and Host Conference Call and Webcast on August 11
8/9/2022
Taysha Gene Therapies, Inc. announced that it will report its financial results for the second quarter ended June 30, 2022, and host a corporate update conference call and webcast on Thursday, August 11, 2022, at 8:00 AM Eastern Time.
-
Rallybio Appoints Wendy K. Chung, M.D., Ph.D., to Its Board of Directors
8/2/2022
Rallybio Corporation today announced that it has appointed Wendy K. Chung, M.D., Ph.D., to its Board of Directors.
-
Taysha Gene Therapies to Participate in Upcoming August Investor Conferences
8/1/2022
Taysha Gene Therapies, Inc. today announced its participation in panel discussions at the BTIG Biotechnology Conference on August 8th and the 2022 Wedbush PacGrow Healthcare Virtual Conference on August 10th.
-
BridgeBio released early data from its Phase I/II CANaspire clinical trial, indicating that BBP-812 might be a promising gene therapy for the ultra-rare Canavan disease.
-
Taysha Gene Therapies Announces Annual Stockholder MeetingThe Annual Stockholder Meeting on Friday, June 17, 2022 at 10 am ET
6/13/2022
Taysha Gene Therapies, Inc. today announced that its annual stockholder meeting will be held on Friday, June 17, 2022 at 10 am ET via webcast.
-
Taysha Gene Therapies to Participate in Upcoming June 2022 Investor Conferences and Convention
6/2/2022
Taysha Gene Therapies, Inc. announced its participation in a fireside chat at the Jefferies Healthcare Conference, Goldman Sachs 43rd Annual Global Healthcare Conference, and JMP Securities Life Sciences Conference.
-
BridgeBio Pharma and its affiliate Phoenix Tissue Repair announced positive data from their Phase II clinical trial for the treatment of recessive dystrophic epidermolysis bullosa (RDEB).
-
Taysha Gene Therapies Reports First Quarter 2022 Financial Results and Provides Corporate Update
5/16/2022
Taysha Gene Therapies, Inc. reported financial results for the first quarter ended March 31, 2022 and provided a corporate update.
-
BridgeBio said it would sell the voucher for $110 million but did not disclose the identity of the company planning to acquire the voucher.
-
BridgeBio announced it has signed an exclusive deal with Bristol-Myers Squibb to develop and commercialize a potential treatment for cancer.
-
Taysha Gene Therapies to Release First Quarter 2022 Financial Results and Host Conference Call and Webcast on May 16
5/11/2022
Taysha Gene Therapies, Inc. today announced that it will report its financial results for the first quarter ended March 31, 2022, and host a corporate update conference call and webcast on Monday, May 16, 2022, at 8:00 AM Eastern Time.
-
OncoNano Medicine Announces the Appointment of Elina Lavit as Vice President, Business Development
5/10/2022
OncoNano Medicine, Inc. today announced the appointment of Elina Lavit as Vice President, Business Development.
-
Taysha Gene Therapies Announces Presentations at the Upcoming 25th Annual Meeting of the American Society of Gene & Cell Therapy
5/10/2022
Taysha Gene Therapies, Inc. announced oral and poster presentations and a company-sponsored symposium at the upcoming 25th Annual Meeting of the American Society of Gene & Cell Therapy taking place in Washington, D.C. from May 16-19, 2022.
-
Taysha Gene Therapies Receives Orphan Drug Designation from the European Commission for TSHA-120 for the Treatment of Giant Axon Neuropathy (GAN)
5/3/2022
Taysha Gene Therapies, Inc. today announced that it has been granted orphan drug designation from the European Commission for TSHA-120, an intrathecally dosed AAV9 gene therapy currently in ongoing clinical evaluation for the treatment of giant axonal neuropathy (GAN).
-
Novartis, Nektar and BridgeBio confirm their plans to restructure their operation, including a number of their employees being laid off.
-
Taysha Gene Therapies Announces Oral Presentations at the Upcoming 2022 IRSF Rett Syndrome Scientific Symposium and the ASCEND National Summit
4/25/2022
Taysha Gene Therapies, Inc. (Nasdaq: TSHA), today announced oral presentations at the upcoming International Rett Syndrome Foundation (IRSF) Rett Syndrome Scientific Symposium taking place in Nashville, Tennessee April 26 – 27, 2022, and the ASCEND Rett Syndrome National Summit.
-
Taysha Gene Therapies to Participate in Upcoming Chardan Genetic Medicines and Cell Therapy Manufacturing Summit
4/18/2022
Taysha Gene Therapies, Inc. (Nasdaq: TSHA), today announced its participation in the upcoming panel and fireside chat at the Chardan Genetic Medicines and Cell Therapy Manufacturing Summit.
-
It was a particularly busy week for clinical trial announcements. Let's take a look.
-
Job cuts in biotech tend to occur during the end of a quarter, and the end of this first quarter is no different. Continue reading for news of four biotech companies making workforce layoffs this week.